A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Canadian Cancer Trials Group
Wake Forest University Health Sciences
TG Therapeutics, Inc.
City of Hope Medical Center
King Faisal Specialist Hospital & Research Center
Leaf Vertical Inc.
Northwestern University
National Cancer Institute (NCI)
National Cancer Institute (NCI)